Miach Orthopaedics Names Jamal Rushdy President and Chief Executive Officer
Photo Credit: Miach Orthopaedics, Inc.
Corporate Business News Sponsored by Business Watch Global
WESTBOROUGH, Mass., May 13, 2026 (VSNewsNetwork.com) — Medical device company Miach Orthopaedics, Inc. has appointed Jamal Rushdy as President and Chief Executive Officer, effective May 18. He succeeds Patrick McBrayer, who is stepping down following a planned leadership transition conducted in partnership with the company’s board of directors.
McBrayer will remain in the role until Rushdy formally assumes leadership.
“Patrick joined Miach at a pivotal moment, as we were accelerating commercialization of the BEAR Implant. Under his leadership, the company has established a strong presence in ACL restoration, with the BEAR Implant now used by more than 750 surgeons and to treat over 9,000 patients. Jamal is the right person to build on that foundation and guide Miach through its next phase of growth,” said Joyce Erony, Chairwoman of the Miach Board and Managing Partner at Amzak Health.
@VSNewsNetwork
•
@VSNewsNetwork •
Rushdy brings nearly 30 years of experience in the medical device sector, including leadership roles in orthopedics, sports medicine and regenerative medicine. Most recently, he served as Chief Executive Officer of Arcuro Medical and previously led Collagen Solutions. He has also held senior roles at Tornier and DJO (now Enovis) and was a founding executive at three medtech companies that achieved successful exits.
“Miach has built strong momentum with differentiated technology and compelling clinical evidence behind the BEAR Implant. The opportunity now is to expand use and advance new indications, with the goal of helping people with ACL tears return to an active lifestyle while preserving long-term knee health. I’m excited to work with the Miach team and the orthopedic community to bring the benefits of the BEAR Implant to even more people, and I thank Patrick for his support,” said Rushdy.
The BEAR® (Bridge-Enhanced ACL Restoration) Implant is designed to enable healing of a torn anterior cruciate ligament (ACL) rather than replacing it with a graft, representing an alternative to traditional reconstruction techniques.
During McBrayer’s tenure, Miach secured more than $60 million in funding, expanded commercial adoption of the BEAR Implant and received FDA approval for label updates, including expanded use in pediatric patients and for partial ACL tears, as well as updates related to post-traumatic osteoarthritis risk.
“Miach is entering its next chapter with strong momentum, and it has been an honor to lead the company’s efforts to transform the treatment of ACL tears over the past several years. What this team has accomplished, from bringing the BEAR Implant into broader clinical use to expanding its adoption among surgeons, has been incredibly meaningful. I’m beyond proud of what this team has built and excited about the impact Miach will continue to have in the years ahead,” said McBrayer.
Miach Orthopaedics is headquartered in Westborough, Massachusetts and focuses on surgical implants for connective tissue restoration.
For more information, visit www.miachortho.com.
Source: Miach Orthopaedics, Inc.
